Acute hepatitis C denotes the initial stage of hepatitis C virus infection, marking a critical juncture in disease progression prior to the establishment of long-term viremia [2]. Identifying this phase presents diagnostic difficulties, especially among immunosuppressed, reinfected, or superinfected individuals, because standard serological conversion and viral RNA detection may fail following prior negative results [1].
Disease overview
Acute hepatitis C
急性丙型肝炎
Evidence-backed informationEN 5/7 applicable sections · ZH 5/7 applicable sectionsUpdated Sep 3, 2026
Acute hepatitis C virus infection constitutes a worldwide public health challenge characterized by marked regional differences in incidence rates [1]. Roughly half to seven-tenths of individuals with recent acquisition progress to chronic viremia persisting beyond six months [2]. Although direct-acting antivirals demonstrate strong therapeutic outcomes, preventive vaccines are currently absent [1]. Initiating antiviral therapy promptly during the acute phase is favored over delayed intervention based on economic evaluations [2].
Read the full clinical and epidemiological profile6
Most patients experience a relatively benign clinical trajectory, yet the condition carries a high propensity for chronicity [2]. Clinical recognition is frequently complicated in vulnerable subgroups where antibody seroconversion and nucleic acid amplification testing yield ambiguous results against a background of previous immunity or infection [1]. Prompt identification enables coordinated clinical management aimed at averting progressive hepatic damage [2].
Acute hepatitis C virus infection occurs worldwide but demonstrates considerable geographic disparity in its occurrence patterns [1]. Population vulnerability is concentrated among individuals subjected to unsafe medical practices, injection drug consumption, and those co-infected with human immunodeficiency virus [1]. These distributional patterns underscore targeted screening priorities across diverse healthcare and community settings [1].
The World Health Organization has set a goal to eliminate hepatitis C virus infection as a public health threat by reducing new infections by 90%, and the diagnosis and treatment of recent infection should reduce ongoing transmission in key populations [2].
Preventive strategies currently lack pharmacological vaccination options, necessitating reliance on behavioral and procedural safeguards [1]. Mitigation efforts emphasize strict adherence to universal safety protocols, substance use harm reduction initiatives, and protected sexual practices alongside expanded therapeutic coverage [1]. Early administration of direct-acting antivirals during the acute window is also recommended to interrupt viral persistence and limit community spread [1].
- 1Liu CH et al. Acute hepatitis C virus infection: clinical update and remaining challenges. Clin Mol Hepatol. 2023 Jul. PMID: 36800699. doi: 10.3350/cmh.2022.0349.PubMed: https://pubmed.ncbi.nlm.nih.gov/36800699/
- 2Fasano M et al. Acute Hepatitis C: Current Status and Future Perspectives. Viruses. 2024 Nov 6. PMID: 39599853. doi: 10.3390/v16111739.PubMed: https://pubmed.ncbi.nlm.nih.gov/39599853/
- B17.1
- 1E50.2
Coverage
Reporting countries and regions
Trends by reporting country
Monthly patterns over time
Research Radar
Recent related research
Sex-specific burdens of acute hepatitis B and C and their attributable risk factors in 204 countries and territories, 1990-2021.
Tropical medicine and health
Literature links are provided for discovery and do not alter or validate the surveillance series above.
Data access
Page dataset index with source links and update metadata.
Official sourcesAuthority, cadence, notes12
Australia NINDSS
Australia
Australian national notifiable diseases surveillance dashboard.
Australia NINDSS — Australian Capital Territory
Australian Capital Territory, Australia
Australian NINDSS monthly state/territory notifications for Australian Capital Territory, kept separate from the Australia national aggregate.
Australia NINDSS — New South Wales
New South Wales, Australia
Australian NINDSS monthly state/territory notifications for New South Wales, kept separate from the Australia national aggregate.
Australia NINDSS — Northern Territory
Northern Territory, Australia
Australian NINDSS monthly state/territory notifications for Northern Territory, kept separate from the Australia national aggregate.
Australia NINDSS — Queensland
Queensland, Australia
Australian NINDSS monthly state/territory notifications for Queensland, kept separate from the Australia national aggregate.
Australia NINDSS — Tasmania
Tasmania, Australia
Australian NINDSS monthly state/territory notifications for Tasmania, kept separate from the Australia national aggregate.
Australia NINDSS — Victoria
Victoria, Australia
Australian NINDSS monthly state/territory notifications for Victoria, kept separate from the Australia national aggregate.
Australia NINDSS — Western Australia
Western Australia, Australia
Australian NINDSS monthly state/territory notifications for Western Australia, kept separate from the Australia national aggregate.
Singapore CDA Weekly Infectious Diseases Bulletin
Singapore
Singapore national weekly case notifications, combining the official data.gov.sg 2012–2022 CSV history with CDA annual workbooks from 2023 onward; 2023 weekly PDFs are retained as a source fallback.
Taiwan, China CDC NIDSS
Taiwan, China
Taiwan, China monthly notifiable infectious disease open-data CSV feed.
US CDC NNDSS
United States
CDC National Notifiable Diseases Surveillance System provisional data.
US CDC NHSS HIV
United States
CDC NNDSS weekly data plus NHSS annual national HIV diagnoses